A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Salmeterol (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neothetics
- 23 Mar 2017 Status changed from recruiting to discontinued, as reported in a Neothetics media release.
- 02 Jul 2015 New trial record
- 30 Jun 2015 According to a company media release, this is a supplemental safety study that Neothetics expects to submit to the US FDA as part of the company's NDA package for LIPO-202, which the company anticipates filing in the second half of 2016.